Dragon Pharma FOXO4-DRI 10 mg is supplied as a lyophilized powder in a 2 mL vial and contains the experimental senolytic peptide FOXO4-DRI at a labeled strength of 10 mg/vial. Product specifications, storage information, and other practical product details are provided below.
10 mg/Vial Strength
Each vial is labeled at 10 mg of FOXO4-DRI peptide.
2 mL Vial
Supplied as a lyophilized powder in a sealed 2 mL vial.
Lyophilized Form
Supplied as a freeze-dried powder for reconstitution with bacteriostatic water or suitable diluent.
Dragon Pharma
Manufactured and packaged under the Dragon Pharma product line.
Product Specifications
Product name
FOXO4-DRI 10 mg
Active substance
FOXO4-DRI
Labeled strength
10 mg/vial
Container
2 mL vial
Product form
Lyophilized powder
Manufacturer
Dragon Pharma
Related Products
Other research peptides available from Dragon Pharma include Epitalon 50 mg, a peptide researched for its potential effects on cellular aging, and SS-31 50 mg, a peptide researched for mitochondrial function. Each has a distinct research profile and mechanism of action.
Science & Research
Understanding FOXO4-DRI
FOXO4-DRI is an experimental D-retro-inverso peptide designed as a senolytic agent. It is researched for its potential to selectively induce apoptosis in senescent cells by disrupting the interaction between the FOXO4 transcription factor and the p53 protein, a key pathway involved in cellular senescence.
1
Senolytic Agent
FOXO4-DRI is researched as a senolytic compound designed to selectively clear senescent cells from tissues.
2
FOXO4-p53 Disruption
The peptide is designed to block the interaction between FOXO4 and p53, which is a pathway that protects senescent cells from apoptosis.
3
D-Retro-Inverso Design
FOXO4-DRI uses D-retro-inverso peptide technology, which reverses the amino acid sequence and uses D-amino acids to improve stability and resistance to enzymatic degradation.
Mechanism of Action
FOXO4-DRI is a synthetic peptide designed to target senescent cells — cells that have stopped dividing and accumulate with age. The peptide works by disrupting the interaction between the FOXO4 transcription factor and the p53 tumor suppressor protein. In senescent cells, this interaction helps protect the cells from apoptosis. By blocking this interaction, FOXO4-DRI is designed to promote apoptosis specifically in senescent cells.
The peptide employs D-retro-inverso technology, meaning the amino acid sequence is reversed and D-amino acids are used instead of L-amino acids. This structural modification is intended to enhance peptide stability and resistance to enzymatic degradation in biological systems.
Research Context
In preclinical animal studies, FOXO4-DRI has been investigated for its potential to improve fitness, kidney function, and reduce markers of frailty through the clearance of senescent cells. These findings have contributed to interest in senolytic compounds as a research area in aging biology.
Dragon Pharma FOXO4-DRI 10 mg is supplied as a lyophilized powder in a 2 mL vial at a labeled strength of 10 mg/vial.
Research References
FOXO4-DRI has been the subject of preclinical research investigating its properties and potential applications in cellular senescence.
FOXO4-DRI is an experimental research peptide with limited safety data in humans. As a compound designed to induce apoptosis in senescent cells, its use requires careful consideration of potential physiological effects.
Cellular Effects
As a senolytic agent, FOXO4-DRI is designed to induce apoptosis in senescent cells. The full scope of effects on different cell types is not fully characterized.
Injection Site Reactions
Reconstituted peptides may cause localized reactions at the injection site. Proper aseptic technique is essential for preparation and administration.
Systemic Effects
The clearance of senescent cells may have systemic effects that are not fully understood. Individuals with pre-existing conditions should exercise caution.
Pregnancy and Breastfeeding
FOXO4-DRI is not indicated for use during pregnancy or breastfeeding. Its effects on fetal development and infant health are not established.
Conditions That Require Medical Review
Medical advice is particularly important when there is a history of autoimmune conditions, cancer, or when taking medications that may interact with cellular signaling pathways.
The product should also be stored securely to prevent accidental access or use by children or other household members.
When to Seek Urgent Medical Help
Seek urgent medical attention for symptoms such as severe allergic reactions, chest pain, sudden shortness of breath, fainting, or signs of a serious adverse reaction.
Tested Sport
FOXO4-DRI is not currently listed on the WADA Prohibited List. However, the use of peptides and research compounds may be subject to specific anti-doping rules depending on the sport and governing body. Current requirements should be checked against the relevant anti-doping rules before competition.
Quick answers about FOXO4-DRI 10 mg specifications, storage, shipping, Bitcoin payment and general product information.
What is Dragon Pharma FOXO4-DRI 10 mg?
Dragon Pharma FOXO4-DRI 10 mg is a lyophilized peptide product containing FOXO4-DRI at a labeled strength of 10 mg per vial. It is supplied in a 2 mL vial as a freeze-dried powder.
What is FOXO4-DRI?
FOXO4-DRI is an experimental D-retro-inverso peptide designed as a senolytic agent. It is researched for its potential to selectively induce apoptosis in senescent cells by disrupting the FOXO4-p53 interaction.
What does "senolytic" mean?
"Senolytic" refers to compounds that are researched for their potential to selectively clear senescent cells — cells that have stopped dividing and accumulate in tissues with age. Senolytic research is an area of interest in aging biology.
What is D-retro-inverso peptide technology?
D-retro-inverso technology is a peptide design approach where the amino acid sequence is reversed and D-amino acids are used instead of L-amino acids. This modification is intended to enhance peptide stability and resistance to enzymatic degradation.
Is FOXO4-DRI 10 mg FDA approved?
No. FOXO4-DRI is not FDA-approved for any therapeutic use. It is a research compound intended for laboratory and preclinical research purposes only.
How should FOXO4-DRI 10 mg be stored?
Keep the lyophilized powder in its original packaging and protect it from excessive heat, moisture and direct light. Refer to the product label for specific storage directions regarding temperature and shelf life. Once reconstituted, the solution should be used promptly or stored according to the manufacturer's directions.
Does FOXO4-DRI 10 mg require refrigeration?
Follow the storage instructions printed on the supplied product. Lyophilized peptides often require refrigeration, but specific storage conditions should be verified from the product label.
How long does FOXO4-DRI 10 mg delivery take?
Delivery depends on the warehouse selected for the order. Shipments from the USA Warehouse typically take 4–5 business days after dispatch, while shipments from the International Warehouse typically take 15–20 business days after dispatch. Full delivery and reship information is available on the Shipping Information page.
Can I buy FOXO4-DRI 10 mg with Bitcoin?
Yes. Bitcoin and other supported cryptocurrencies are available at checkout for all orders. To buy FOXO4-DRI 10 mg with Bitcoin, select Bitcoin as the payment method during checkout and follow the payment instructions provided with the order.
Is Bitcoin payment anonymous?
Bitcoin transactions are recorded on a public blockchain and should not be considered automatically anonymous. Accurate order and delivery information is still required for order processing and shipping.
Is FOXO4-DRI permitted in tested sport?
FOXO4-DRI is not currently listed on the WADA Prohibited List. However, the use of peptides and research compounds may be subject to specific anti-doping rules depending on the sport and governing body. Current requirements should be checked against the relevant anti-doping rules before competition.
Where can I find more information about FOXO4-DRI?
Additional information about FOXO4-DRI is available through PubMed and other research literature databases. Direct links are provided in the Science & Research section above.
